Defining Success: Trump and Kennedy’s Path to Winning on Health in 2026

Commentary

As President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. chart the course for America’s health in 2026, their ambitious “Make America Healthy Again” (MAHA) agenda faces a defining moment. With chronic disease rates soaring, public skepticism about COVID vaccines growing, autism diagnoses rising, and drug prices burdening families, the administration’s success hinges on delivering tangible results in these critical areas. To win on health, Trump and Kennedy must combine bold policy reforms with transparent, evidence-based action, restoring trust while addressing the nation’s pressing health challenges.

Tackling Chronic Disease: A National Priority

Chronic diseases—obesity, diabetes, cancer, and heart disease—afflict six in 10 Americans, with four in 10 battling multiple conditions. The White House’s MAHA Commission, established by Trump’s February 2025 Executive Order and chaired by Kennedy, aims to reverse this trend by investigating root causes, from poor nutrition to environmental exposures. Success in 2026, requires the commission to deliver its promised 180-day strategy with actionable recommendations. For instance, phasing out synthetic food dyes and limiting food stamp purchases of sugary drinks, as Kennedy has proposed, could shift dietary habits.

If the commission’s report translates into policies that measurably reduce chronic disease rates—say, a definable drop in prediabetes among teens—Trump and Kennedy will earn public trust and prove their approach works.

Addressing COVID Vaccines: Restoring Confidence

Public confidence in COVID vaccines has wavered amid concerns about side effects and mandates. Kennedy has pledged “radical transparency” in vaccine safety data, while Trump has signaled openness to reviewing vaccine policies. To succeed in 2026, they must balance scrutiny with science. The administration should prioritize releasing comprehensive, de-identified vaccine safety data to the public, addressing concerns about side effects like myocarditis. Additionally, the biggest win will likely come in removing the COVID vaccine from the childhood immunization schedule, which there is a growing body of evidence to support.

Confronting Autism: Science Over Speculation

Autism diagnoses have surged, with the CDC reporting a rise from one in 36 children in 2020 to one in 31 in 2022. To win on this issue, the administration must focus on robust research. HHS’s planned autism studies, announced for 2025, must employ gold-standard methods. Success means producing a September 2026 report that identifies credible environmental, genetic or vaccine related factors. All factors should be on the table to ensure the American public can view a well-rounded and robust report that doesn’t shy away from data.

Lowering Drug Prices: Delivering Relief

High drug prices remain a top concern, with Americans paying substantially more for certain drugs than their European counterparts. Trump’s April 2025 Executive Order on drug pricing, which expands Medicare negotiations, streamlines generic approvals, and revives drug importation, builds on his first-term efforts. To succeed in 2026, Trump and Kennedy must ensure these policies yield measurable savings. For example, if Medicare’s expanded negotiations cut costs for an additional 20 drugs by 30 percent or more, seniors will feel direct relief. Advancing importation programs, like Florida’s Canadian drug initiative, could lower prices for millions. Transparency in pharmacy benefit manager practices, as targeted by the order, must also expose hidden costs. Success will be judged by whether families see lower out-of-pocket expenses.

The Road to Victory

Winning on health in 2026 demands results, not just rhetoric. Trump and Kennedy must deliver a MAHA Commission strategy that curbs chronic disease through practical reforms, like healthier school lunches and food additive bans. They need to address COVID vaccine concerns with transparent data. On autism, they must fund rigorous studies that respect scientific consensus and autistic communities. And on drug prices, they must drive down costs through negotiation, competition, and importation.

If Trump and Kennedy can show declining chronic disease rates, movement on the COVID vaccine, credible autism research, and lower drug bills by 2026, they’ll prove MAHA is more than a slogan. For millions of Americans desperate for a healthier future, that’s the victory that matters.

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times.